Enovis (ENOV) Stock News

Enovis (NYSE: ENOV) has appointed Tim Czartoski as President of U.S. Surgical and Global Product and Enabling Technologies. Czartoski, who reports to Louie Vogt, Group President of Enovis' Reconstructive Business Group, brings over 22 years of experience from Depuy Synthes, Johnson & Johnson's Orthopaedics Company. In his previous role, he led Depuy Synthes' U.S. operations, overseeing joint reconstruction, trauma, spine, digital technology, capital, sports, and CMF businesses.

Czartoski's appointment is expected to accelerate Enovis' growth potential and strengthen its surgical pipeline globally. His educational background includes a B.S. from Ohio State University, an M.S. in Technology Management from Columbia, and an MBA from Notre Dame.

Enovis™ (NYSE: ENOV), a medical technology company, is set to unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting from September 11–14, 2024, in Vancouver. The Tarsoplasty system aims to reduce operative time and improve patient recovery outcomes for bunionectomy procedures. Better Step enhances the patient experience throughout bunion surgery recovery. Enovis will also showcase other advanced solutions, including the DynaNail® TTC Fusion System, Evolve34™ Lapidus Correction System, and expanded options for the Arsenal Foot Plating System.

Enovis (NYSE: ENOV) has expanded its EMPOWR Revision Knee™ system with the addition of EMPOWR™ Cones, creating a comprehensive portfolio for complex revision knee surgeries. The FDA-cleared cones include stackable tibial, femoral, and diaphyseal options to treat bone defects. This expansion aims to redefine revision knee arthroplasty by offering a streamlined yet comprehensive setup, reducing operating room clutter while allowing surgeons to fine-tune implant fit.

The system's features include femoral and tibial stackable augments usable both medially and laterally, minimizing excess inventory. Multifunctional instrumentation keeps the surgeon's back table organized, streamlining procedures. The addition of EMPOWR Cones provides surgeons with greater flexibility in tailoring revision surgeries, addressing a market need for more efficient revision options, particularly with growing interest in outpatient procedures.

Enovis (NYSE: ENOV) has introduced the STAR® Ankle with new e+™ Polyethylene, following FDA approval. This makes it the first and only mobile bearing ankle system with e+™ Polyethylene in the United States. The implant's vitamin E-blended insert offers improved durability, stability, and longevity.

Key features of e+™ Polyethylene include:

• Resistance to oxidation
• Consistent wear rates
• Stable mechanical properties over time

The STAR® Ankle has been used globally over 40,000 times across its 37-year history. This innovation, combined with the recent release of STAR Patient Specific Instrumentation (PSI), represents Enovis' commitment to enhancing patient satisfaction and outcomes in foot and ankle solutions.

Enovis (NYSE: ENOV), a medical technology growth company, has announced its participation in three upcoming investor conferences:

• Canaccord Genuity 44th Annual Growth Conference on August 13th
• Wells Fargo Healthcare Conference on September 5th
• Baird 2024 Global Healthcare Conference on September 11th

The company's management team, including CFO Ben Berry and CEO Matt Trerotola, will participate in fireside chats at these events. Live audio webcasts and replays will be available on Enovis' website under the Investors tab. Enovis is dedicated to developing clinically differentiated solutions for better patient outcomes and improved workflows in orthopedics and beyond.

Enovis (NYSE: ENOV) reported strong Q2 2024 results with 23% sales growth to $525 million and adjusted EBITDA margin expansion of 190 basis points to 17.2%. The company saw 60% reported growth in Recon and 2% in P&R. Despite a net loss of $0.34 per share, adjusted earnings were $0.62 per share. Enovis received FDA clearances for Arvis 2.0 Shoulder and Altivate Reverse Glenoid system, opened a Business Technology Center in Lisbon, and a new manufacturing facility in San Daniele. The company narrowed its 2024 revenue guidance to $2.08-$2.13 billion, reaffirmed adjusted EBITDA expectations of $368-$383 million, and raised adjusted EPS guidance to $2.62-$2.77.

Enovis (NYSE: ENOV), a medical technology growth company, has announced a time change for its Second Quarter 2024 results conference call. The call will now take place on August 7, 2024, at 8:00 a.m. Eastern Time, earlier than previously scheduled. The date and other details remain unchanged. Investors can access the live webcast through the Enovis website. For call participation, U.S. callers should dial (833) 685-0901, while international callers should use (412) 317-5715. A presentation related to the call will be available on ir.enovis.com, and a replay link will be provided on the website later that day.

Enovis (NYSE: ENOV), a medical technology growth company, has announced its upcoming second quarter 2024 financial results conference call. The event is scheduled for Wednesday, August 7, 2024, at 8:30 a.m. Eastern Time. An earnings press release will be issued earlier that morning, and a related presentation will be available on the company's investor relations website.

Investors can access the live webcast through the Enovis website. For those participating via phone, the dial-in numbers are (833) 685-0901 for U.S. callers and (412) 317-5715 for International callers. Participants should request to join the Enovis call. A replay of the call will be made available on the company's website later that day.

Enovis™ (NYSE: ENOV) has launched the AltiVate Reverse® Glenoid System, enhancing its market-leading AltiVate Reverse line. This new system, which received FDA 510(k) clearance in May 2024, offers modular, augmented baseplates and bone-sparing options, aiming to broaden the range of patients suitable for reverse shoulder arthroplasty. The first surgery using this system was performed by Dr. Mark Frankle at Tampa General Hospital on July 8, 2024. The system includes neutral and 15° wedge options, various central compression screw lengths, and four new glenospheres to optimize patient outcomes. Reverse shoulder arthroplasty accounts for over 60% of the 200,000+ annual shoulder replacements in the U.S., highlighting the growing demand for versatile implants. Enovis continues to prioritize surgeon-driven innovation and patient care through its comprehensive and efficient solutions.